Disclaimer:

Medidex is not a provider of medical services and all information is provided for the convenience of the user. No medical decisions should be made based on the information provided on this website without first consulting a licensed healthcare provider.This website is intended for persons 18 years or older. No person under 18 should consult this website without the permission of a parent or guardian.

cangrelor

×

Overview

What is KENGREAL?

KENGREAL is a direct-acting P2Y platelet receptor inhibitor that blocks adenosine diphosphate (ADP)-induced platelet activation and aggregation. The chemical structure is similar to adenosine triphosphate (ATP).

The chemical name of KENGREAL is tetrasodium salt of N6-[2-(methylthio)ethyl]-2-[(3,3,3,-trifluoropropyl)-5’-adenylic acid, monanhydride with (dichloromethylene) bisphosphonic acid.

The empirical formula of KENGREAL is CHNCFNaOPS and the molecular weight is 864.3 g/mol.

The chemical structure is represented below:

Cangrelor for Injection is a sterile white to off-white lyophilized powder for IV infusion. In addition to the active ingredient, cangrelor, each single use vial contains mannitol, sorbitol, and sodium hydroxide to adjust the pH.



What does KENGREAL look like?



What are the available doses of KENGREAL?

Single-use 10 mL vial containing 50 mg KENGREAL as a lyophilized powder for reconstitution ()

What should I talk to my health care provider before I take KENGREAL?

How should I use KENGREAL?

KENGREAL is indicated as an adjunct to percutaneous coronary intervention (PCI) to reduce the risk of periprocedural myocardial infarction (MI), repeat coronary revascularization, and stent thrombosis (ST) in patients who have not been treated with a P2Y platelet inhibitor and are not being given a glycoprotein IIb/IIIa inhibitor

The recommended dosage of KENGREAL is a 30 mcg/kg IV bolus followed immediately by a 4 mcg/kg/min IV infusion. Initiate the bolus infusion prior to PCI. The maintenance infusion should ordinarily be continued for at least 2 hours or for the duration of PCI, whichever is longer.


What interacts with KENGREAL?

Sorry No Records found


What are the warnings of KENGREAL?

Sorry No Records found


What are the precautions of KENGREAL?

Sorry No Records found


What are the side effects of KENGREAL?

Sorry No records found


What should I look out for while using KENGREAL?

Significant active bleeding ()

Hypersensitivity to KENGREAL or any component of the product ()


What might happen if I take too much KENGREAL?

There is no specific treatment to reverse the antiplatelet effect of KENGREAL but the effect is gone within one hour after the drug is discontinued.

In clinical trials, 36 patients received an overdose of KENGREAL, ranging from 36 to 300 mcg/kg (bolus dose) or 4.8 to 13.7 mcg/kg/min (infusion dose). The maximum overdose received was 10 times the PCI bolus dose or 3.5 times the PCI infusion dose in 4 patients. No clinical sequela were noted as a result of overdose following completion of KENGREAL therapy.


How should I store and handle KENGREAL?

Store at 25°C (77°F); excursions permitted to 15 to 30°C (59 to 86°F) [see USP Controlled Room Temperature]. Pharmacist: Dispense in a tight, light-resistant container with a child-resistant closure and medication guide. Store at 25°C (77°F); excursions permitted to 15 to 30°C (59 to 86°F) [see USP Controlled Room Temperature]. Pharmacist: Dispense in a tight, light-resistant container with a child-resistant closure and medication guide. KENGREAL is supplied as a sterile lyophilized powder in single-use 10 mL vials.Vials of KENGREAL should be stored at USP Controlled Room Temperature, [20°C to 25°C (68°F to 77°F) with excursions between 15°C and 30°C (59°F and 86°F) permitted]. KENGREALis a registered trademeark of Chiesi Farmaceutici S.p.A.Distributed by:Chiesi USA, Inc. Cary, NC  27518CTK-001-0816-00-SPLKENGREAL is supplied as a sterile lyophilized powder in single-use 10 mL vials.Vials of KENGREAL should be stored at USP Controlled Room Temperature, [20°C to 25°C (68°F to 77°F) with excursions between 15°C and 30°C (59°F and 86°F) permitted]. KENGREALis a registered trademeark of Chiesi Farmaceutici S.p.A.Distributed by:Chiesi USA, Inc. Cary, NC  27518CTK-001-0816-00-SPLKENGREAL is supplied as a sterile lyophilized powder in single-use 10 mL vials.Vials of KENGREAL should be stored at USP Controlled Room Temperature, [20°C to 25°C (68°F to 77°F) with excursions between 15°C and 30°C (59°F and 86°F) permitted]. KENGREALis a registered trademeark of Chiesi Farmaceutici S.p.A.Distributed by:Chiesi USA, Inc. Cary, NC  27518CTK-001-0816-00-SPLKENGREAL is supplied as a sterile lyophilized powder in single-use 10 mL vials.Vials of KENGREAL should be stored at USP Controlled Room Temperature, [20°C to 25°C (68°F to 77°F) with excursions between 15°C and 30°C (59°F and 86°F) permitted]. KENGREALis a registered trademeark of Chiesi Farmaceutici S.p.A.Distributed by:Chiesi USA, Inc. Cary, NC  27518CTK-001-0816-00-SPLKENGREAL is supplied as a sterile lyophilized powder in single-use 10 mL vials.Vials of KENGREAL should be stored at USP Controlled Room Temperature, [20°C to 25°C (68°F to 77°F) with excursions between 15°C and 30°C (59°F and 86°F) permitted]. KENGREALis a registered trademeark of Chiesi Farmaceutici S.p.A.Distributed by:Chiesi USA, Inc. Cary, NC  27518CTK-001-0816-00-SPL


×

Clinical Information

Chemical Structure

No Image found
Clinical Pharmacology

Cangrelor is a direct P2Y platelet receptor inhibitor that blocks ADP-induced platelet activation and aggregation. Cangrelor binds selectively and reversibly to the P2Y receptor to prevent further signaling and platelet activation.

Non-Clinical Toxicology
Significant active bleeding ()

Hypersensitivity to KENGREAL or any component of the product ()

Drugs that inhibit platelet P2Y function, including KENGREAL, increase the risk of bleeding.

In CHAMPION PHOENIX bleeding events of all severities were more common with KENGREAL than with clopidogrel . Bleeding complications with KENGREAL were consistent across a variety of clinically important subgroups (see Figure 1).

Once KENGREAL is discontinued, there is no antiplatelet effect after an hour .

The following adverse reactions are also discussed elsewhere in the labeling:

×

Reference

This information is obtained from the National Institute of Health's Standard Packaging Label drug database.
"https://dailymed.nlm.nih.gov/dailymed/"

While we update our database periodically, we cannot guarantee it is always updated to the latest version.

×

Review

Rate this treatment and share your opinion


Learn about User Reviews

Helpful tips to write a good review:

  1. Only share your first hand experience as a consumer or a care giver.
  2. Describe your experience in the Comments area including the benefits, side effects and how it has worked for you. Do not provide personal information like email addresses or telephone numbers.
  3. Fill in the optional information to help other users benefit from your review.

Reason for Taking This Treatment

(required)

Click the stars to rate this treatment

Effectiveness (required)

This medication has worked for me.




Ease of Use (required)

This medication has been easy for me to use.




Satisfaction (required)

Overall, I have been satisfied with my experience.




Write a brief description of your experience with this treatment:

2000 characters remaining

Optional Information

Help others benefit from your review by filling in the information below.
I am a:
Gender:
×

Professional

Clonazepam Description Each single-scored tablet, for oral administration, contains 0.5 mg, 1 mg, or 2 mg Clonazepam, USP, a benzodiazepine. Each tablet also contains corn starch, lactose monohydrate, magnesium stearate, microcrystalline cellulose, and povidone. Clonazepam tablets USP 0.5 mg contain Yellow D&C No. 10 Aluminum Lake. Clonazepam tablets USP 1 mg contain Yellow D&C No. 10 Aluminum Lake, as well as FD&C Blue No. 1 Aluminum Lake. Chemically, Clonazepam, USP is 5-(o-chlorophenyl)-1,3-dihydro-7-nitro-2H-1,4-benzodiazepin-2-one. It is a light yellow crystalline powder. It has the following structural formula: C15H10ClN3O3 M.W. 315.72
×

Tips

Tips

×

Interactions

Interactions

A total of 440 drugs (1549 brand and generic names) are known to interact with Imbruvica (ibrutinib). 228 major drug interactions (854 brand and generic names) 210 moderate drug interactions (691 brand and generic names) 2 minor drug interactions (4 brand and generic names) Show all medications in the database that may interact with Imbruvica (ibrutinib).